重要内容提示: 公司控股股东、实际控制人梁耀铭先生直接持有公司股份 74,191,907 股，占公司总股本的 16.02%。本次解除质押股份 6,550,000 股，占梁耀铭先生 直接持有公司股份数的 8.83%，占公司总股本的 1.41%。 本次股份解除质押后，公司控股股东、实际控制人梁耀铭先生及其一致 行动人严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及 锐致累计质押 31,580,000 股，占其持有公司股份总数的 19.14%，占公司总股本 的 6.82%。 一、上市公司股份解除质押 广州金域医学检验集团股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日接到公司控股股东、实际控制人梁耀铭先生通知，获悉其质押给中信证券股份 有限公司的部分公司股份已办理解除质押手续，具体事项如下： | 股东名称 | 梁耀铭 | | --- | --- | | 本次解除质押股份（股） | 6,550,000 | | 占其所持股份比例 | 8.83% | | 占公司总股本比例 | 1.41% | | 解除质押时间 | 2025 年 4 月 7 日 | | 持股数量（股） | 74,191,90 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-014 广州金域医学检验集团股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 公司控股股东、实际控制人梁耀铭先生直接持有公司股份74,191,907股，占公司总股本的16.02%。本 次质押股份7,000,000股，占梁耀铭先生直接持有公司股份数的9.43%，占公司总股本的1.51%。 ● 本次股份质押后，公司控股股东、实际控制人梁耀铭先生及其一致行动人严婷女士、曾湛文先生以及 梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及锐致累计质押38,130,000股，占其持有公司股份总数的 23.11%，占公司总股本的8.23%。 一、上市公司股份质押 广州金域医学检验集团股份有限公司（以下简称"公司"）于2025年4月3日接到公司控股股东、实际控制 人梁耀铭先生通知，获悉梁耀铭先生所持有本公司的部分股份被质押。具体事项如下： 1.本次股份质押基本情况 ■ 2025年4月4日 广州金域医学检验集团股份有 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-014 广州金域医学检验集团股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东、实际控制人梁耀铭先生直接持有公司股份 74,191,907 股， 占公司总股本的 16.02%。本次质押股份 7,000,000 股，占梁耀铭先生直接持有 公司股份数的 9.43%，占公司总股本的 1.51%。 本次股份质押后，公司控股股东、实际控制人梁耀铭先生及其一致行动人 严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及锐致 累计质押 38,130,000 股，占其持有公司股份总数的 23.11%，占公司总股本的 8.23%。 一、上市公司股份质押 广州金域医学检验集团股份有限公司（以下简称"公司"）于 2025 年 4 月 3 日接到公司控股股东、实际控制人梁耀铭先生通知，获悉梁耀铭先生所持有本公 司的部分股份被质押。具体事项如下： 2.本次质押股份不涉及被用作重大资产重组业绩补偿 ...

[Table_Page] 公司深度研究|医疗服务 证券研究报告 | [Table_Title] 金域医学（603882.SH） | | --- | 数据资产价值重估，AI 技术驱动创新应用 场景拓展 [Table_Summary] 核心观点： | 基本数据 [Table_BaseInfo] | | | --- | --- | | 总股本/流通股本（百万股） | 463.26/460.13 | | 总市值/流通市值（百万元） | 14856.69/14756.52 | | 一年内最高/最低（元） | 56.05/24.44 | | 30 日日均成交量/成交额（百万） | 13.42/479.51 | | 近 3 个月/6 个月涨跌幅（%） | 21.92/-17.83 | [Table_PicQuote] 相对市场表现 -60% -44% -28% -12% 4% 20% 04/24 05/24 07/24 09/24 11/24 01/25 03/25 金域医学 沪深300 | [分析师： Table_Author]罗佳荣 | | | --- | --- | | | SAC 执证号：S026051609000 ...

投资者 大家下午好非常感谢大家今天在周末的下午能够抽出时间参加我们的精英医学深度报告解读会 那么国际医药也是最近隆重推出了精英医学的深度报告那么在这个报告中我们对公司过去的业绩的发展作为中国的ICL龙头它的业务的发展包括福建业务还有特点业务的一个升级更新以及公司在公共卫生事件后的业务恢复的趋势做了一个分析和解读与此同时我们在本报告中也把重点往 公司的AI数字化转型、项本灯效以及新业务的拓展这一块做了一个梳理和展望那么公司推出了像预见一样的大模型以及配套的智能应用小御衣同时公司也有着大量的数据的储备和基建那么未来也有着丰富的数据产品价值 所以综合以上的这些要点呢我们觉得其实整个后续公司既有主要的是恢复逻辑又有AI应用和这个数据升级的逻辑那么这两种这个两种这个动力相结合呢我觉得公司未来的发展也会再上一个台阶那么大家可以看到春节以后呢公司的这个整体表现还是非常强劲的虽然最近有一个回调啊但是我们认为就是 考虑到公司的这个业务的主业的复苏和它的一个目前还非常有性价比的一个估值水平我们是看好公司走出一个更强的横琴而不是短暂的这个一波的这个AI热度所以这也是我们在这个点发出了这个深度报告的一个重要原因那么下面呢我就把我们的 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 43.13 RMB based on a 2025 PS of 2.5X [3]. Core Viewpoints - The company is expected to continue its digital transformation, with improving cash collection rhythms and a positive long-term growth outlook [2][3]. - The industry has significant room for penetration growth, with the leading companies likely to maintain their competitive edge [1][3]. Summary by Sections Industry Overview - The Independent Clinical Laboratory (ICL) industry in China has a penetration rate of less than 10%, significantly lower than developed countries like Japan, which has a 60% penetration rate, indicating substantial growth potential [7][19]. - The industry is currently in an accelerated development phase, with a trend towards consolidation as smaller players exit the market due to declining demand for specific tests [38][41]. Policy Environment - The implementation of hierarchical diagnosis and treatment, along with medical insurance payment reforms, is driving the growth of the ICL industry [20][23]. - The LDT (Laboratory Developed Tests) pilot programs are being rolled out, allowing for innovation in testing methods and expanding the market for ICL services [26][29]. Company Overview - The company, established in 2003, focuses on third-party medical testing and has a nationwide laboratory network covering 90% of the population [30]. - The company operates 49 self-built laboratories and over 750 cooperative laboratories, making it a market leader in terms of scale and service coverage [30][31]. Financial Performance - The company’s revenue for 2024-2026 is projected to be 76.72 billion, 79.87 billion, and 82.39 billion RMB, respectively, with expected net profits of -3.52 billion, 1.47 billion, and 5.14 billion RMB [3][6]. - The company has experienced a compound annual growth rate (CAGR) of 32.1% in revenue and 54.6% in net profit from 2012 to 2021, although it anticipates a loss in 2024 due to high fixed costs and extended receivables collection periods [31][32]. Digital Transformation - The company is advancing its digital transformation to reduce operational costs, enhance service efficiency, and improve customer experience [48][50]. - The introduction of AI models and digital platforms aims to streamline processes and provide better support for healthcare professionals [49][50].

Summary of Jin Domain Medical Conference Call Company Overview - Jin Domain Medical is a pioneer in China's third-party medical testing industry, established for 30 years, focusing on both core medical testing and the accumulation of professional data from frontline operations [2][4]. Key Achievements and Developments - **Digital Transformation**: Initiated in 2020 due to the COVID-19 pandemic, focusing on technology and data infrastructure, business digitization, and the development of digital business [2]. - **Data Management**: Successfully standardized and structured data management from 23,000 hospitals, laying the groundwork for future AI applications and data products [2]. - **AI Integration**: Since 2014, the company has invested in AI-assisted diagnosis, notably collaborating with Huawei to launch an AI-assisted cervical cancer screening application, improving pathologist efficiency by four times [2][4]. - **Large Model Technology**: Began research in 2019, developing the "Red Leaf Model" and its application "Encounter One Yuan," with a service platform for clinical doctors registering 520,000 users [2][6]. - **Data Volume**: Holds over 24PB of data, with an annual increase of approximately 1PB, covering a wide population and over 4,000 testing items, ensuring high medical value [2][7]. Industry Position and Recognition - **Regulatory Approval**: The only company in the third-party medical testing field to receive algorithm registration from the Central Cyberspace Administration of China, demonstrating algorithm capability and data quality [2][9]. - **Competition and Market Penetration**: Current market penetration is about 10%, significantly lower than in Europe and the US, indicating substantial growth potential [15]. Future Directions - **Continued AI Development**: Plans to deepen research in large model technology, integrating advanced reasoning capabilities like GPT-4 to enhance medical reasoning in complex scenarios [11]. - **Digital Solutions**: Aiming to launch a new generation of digital empowerment solutions for medical communities in 2025, furthering digital transformation efforts [15]. - **Data Trading**: The company has launched data products in a data exchange, targeting pharmaceutical companies, insurance firms, and public health institutions, with a projected market size in the hundreds of billions [22]. Challenges and Responses - **Data Completeness Concerns**: The company assures that its data quality and completeness are among the best in the industry, addressing concerns about training data integrity and clinical decision-making support [10][24]. - **AI Assistant Demand**: Recognizes high demand for AI assistants among grassroots clinical doctors, focusing on developing intelligent solutions tailored to their needs [18]. Revenue Generation - **AI and Digital Tools**: Revenue streams include cost reduction and efficiency improvements, direct sales from COVID-19 screening systems, and empowering upstream and downstream manufacturers with AI capabilities [15][21]. Conclusion - Jin Domain Medical is positioned as a leader in the third-party medical testing industry, leveraging advanced technology and data management to enhance medical services and efficiency, while actively pursuing growth opportunities in AI and digital solutions.

证券代码：603882 证券简称：金域医学 公告编号：2025-013 广州金域医学检验集团股份有限公司 2024 年前三季度 权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.88 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/2/20 | － | 2025/2/21 | 2025/2/21 | 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 本次利润分配方案经广州金域医学检验集团股份有限公司（以下简称"公司"） 2025 年 2 月 7 日的 2025 年第一次临时股东会审议通过。 二、分配方案 1.发放年度：2024 年前三季度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： ...

Summary of Jin Domain Medical Conference Call Company Overview - **Company**: Jin Domain Medical - **Industry**: Medical Diagnostics and AI Integration Key Points and Arguments AI Development and Applications - Jin Domain Medical began exploring AI in 2014 with the "Xiao Jin" model for pathology diagnosis, and in 2023, established a large model project team to enhance AI capabilities [3][4] - The company launched the industry large model "Yujian Yiyan" and the smart application "Xiao Yuyi" in 2024, achieving full-scene intelligence in medical testing services, including experience sharing, report interpretation, project recommendations, and clinical decision support [3][4] - Jin Domain Medical has accumulated 24 petabytes (P) of medical testing data, adding 1P annually, covering 90% of China's population and serving 23,000 hospitals with over 4,000 testing projects, providing a robust data foundation for AI product development [3][5] Data and Compliance - The company received a license from the Guangdong Provincial Department of Science and Technology for an "Open Innovation Platform for AI in Medical Testing and Pathology Diagnosis," allowing for data resource accumulation and ecosystem expansion [6] - Jin Domain Medical emphasizes high-quality data characterized by large volume, wide coverage, and high standardization, adhering strictly to national personal information protection regulations [12] Model Performance and Validation - The integration of the DeepSeek model has significantly improved capabilities in complex scenarios, enhancing logical clarity and interpretability of reasoning processes, although issues with information completeness and hallucination remain [10][24] - The company has validated the model's performance through functional facilities and scenario testing, showing improvements in accuracy and reasoning capabilities [10] Economic Impact and Business Model - Jin Domain Medical's economic returns stem from three main paths: enhancing laboratory efficiency through AI, providing policy services to doctors, and direct monetization of digital products [21] - AI cervical cancer detection has doubled the efficiency of pathologists, increasing sample processing from 10 million to 20 million, while overall efficiency improved fourfold [21] Future Directions and Challenges - The company aims to develop high-quality early screening products by analyzing the relationship between genes and diseases, leveraging AI to enhance the clinical relevance of genetic testing results [26][27] - Jin Domain Medical anticipates the emergence of significant new products that will transform existing diagnostic methods, driven by technological advancements and big data applications [28] Data Utilization and Market Position - Jin Domain Medical's data is not publicly available but is used within alliances of doctors, ensuring compliance and security in data handling [16][17] - The company differentiates itself from other medical software providers by owning the data generated through its testing services, allowing for unique data processing capabilities [17] Conclusion - Jin Domain Medical is at the forefront of integrating AI into medical diagnostics, with a strong focus on data quality, compliance, and innovative applications that enhance efficiency and clinical decision-making, positioning itself for future growth in the evolving healthcare landscape.

股票交易风险提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司股票交易连续于 2025 年 2 月 5 日、2 月 6 日、2 月 7 日三个交易日 内收盘价格涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关 规定，属于股票交易异常波动情形。公司已于 2025 年 2 月 8 日披露了《广州金 域医学检验集团股份有限公司股票交易异常波动公告》（公告编号：2025-011）。 2025 年 2 月 10 日，公司股票再次涨停，近期公司股票价格波动较大。 经财务部门初步测算，预计公司 2024 年度利润将出现亏损。 公司目前生产经营情况正常，主营业务未发生重大变化，市场环境或行 业政策没有发生重大调整。 敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 广州金域医学检验集团股份有限公司（以下简称"公司"）股票交易于2025 年2月5日、2月6日、2月7日连续三个交易日内收盘价格涨幅偏离值累计超过20%。 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形，公 司 ...